Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
暂无分享,去创建一个
D. Umbenhauer | T R Pippert | D R Umbenhauer | C E Hop | Q Chen | G. Kwei | R W Wang | G Y Kwei | R F Alvaro | H J Jenkins | C A Keohane | V T Ly | J R Strauss | Z Wang | J. Strauss | C. Keohane | T. Pippert | V. Ly | R. Wang | R. Alvaro | C. Hop | Q. Chen | Z. Wang | H. J. Jenkins | C. E. Hop | Qing Chen | Regina W. Wang | Zhen Wang
[1] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[2] J. Kolars,et al. First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.
[3] W B Jakoby,et al. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. , 1974, The Journal of biological chemistry.
[4] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] F. Loor,et al. Decreased biotolerability for ivermectin and cyclosporin a in mice exposed to potent P‐glycoprotein inhibitors , 1995, International journal of cancer.
[6] Y. Tanigawara,et al. Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.
[7] P. Watkins,et al. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. , 1997, Advanced drug delivery reviews.
[8] E. Schuetz,et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.
[9] G R Lankas,et al. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. , 1997, Toxicology and applied pharmacology.
[10] G. Giaccone,et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[12] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[13] M. Brecher,et al. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. , 1993, Anticancer research.
[14] G R Lankas,et al. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. , 1997, Toxicology and applied pharmacology.
[15] B. Beltz,et al. Immunocytochemical Techniques: Principles and Practice , 1989 .
[16] M. Millward,et al. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. , 1993, Journal of the National Cancer Institute.
[17] J. Beijnen,et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.
[18] D. Waxman,et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.
[19] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.
[20] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[21] A. Y. Lu,et al. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[22] G R Lankas,et al. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. , 1998, Reproductive toxicology.
[23] M. Relling,et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. , 1996, Proceedings of the National Academy of Sciences of the United States of America.